Amgen: We Expect To Double Biosimilar Sales By 2030
Interchangeability ‘Not Essential’ But A Differentiator; Ustekinumab Studies Continue
Amgen management paid close attention to the company’s biosimilar portfolio and pipeline during several recent calls with investors, including what differentiates the firm from its rivals in the biosimilars space.
You may also be interested in...
Two of Amgen’s flagship biosimilar products saw a notable drop in sales in Q1 in the face of increased competition, but impending launches are expected to put the unit back on track.
Amgen CEO Robert Bradway has delivered confident predictions for the company’s biosimilars business at the J.P. Morgan Healthcare Conference, with a steady flow of launches expected to give the company’s earnings a significant boost over the coming years.
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.